Skip to main content
Top
Published in: Clinical Rheumatology 5/2006

01-09-2006 | Case Report

Combined CNS and pituitary involvement as a primary manifestation of Wegener granulomatosis

Authors: Radek Špíšek, Elena Kolouchová, Jiří Jenšovský, Robert Rusina, Pavel Fendrych, Jaroslav Plas, Jiřina Bartůňková

Published in: Clinical Rheumatology | Issue 5/2006

Login to get access

Abstract

Wegener granulomatosis (WG) is a systemic vasculitis of small and medium vessels. It predominantly affects the upper and/or lower respiratory airway and kidneys. Its pathogenesis is not fully understood. WG relatively frequently affects the nervous system (in 30–50% according to the different studies). Most frequently, it manifests as necrotizing vasculitis that leads to the peripheral neuropathies or to the cranial nerves palsy. Impairment of the central nervous system (CNS) is less frequent and occurs in 2–8% of patients. Three major pathogenetic mechanisms were described: CNS vasculitis, spreading of granulomas from the adjacent anatomical areas (paranasal cavities, orbit etc.), and new formation of granulomas in brain tissue. This case report describes patients in whom WG manifested in the form of localized skin involvement and combined CNS involvement that included pituitary gland. Atypical presentation of WG impedes and slows down the process of diagnosis and emphasizes the need for collaboration between medical specialists.
Literature
1.
go back to reference Bartunkova J, Tesar V, Sediva A (2003) Diagnostic and pathogenetic role of antineutrophil cytoplasmic autoantibodies. Clin Immunol 106:73–82CrossRefPubMed Bartunkova J, Tesar V, Sediva A (2003) Diagnostic and pathogenetic role of antineutrophil cytoplasmic autoantibodies. Clin Immunol 106:73–82CrossRefPubMed
2.
go back to reference Fauci AS, Haynes BF, Katz P, Wolff SM (1983) Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98:76–85PubMed Fauci AS, Haynes BF, Katz P, Wolff SM (1983) Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98:76–85PubMed
3.
go back to reference Matteson EL, Gold KN, Bloch DA, Hunder GG (1996) Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's granulomatosis classification criteria cohort. Am J Med 101:129–134CrossRefPubMed Matteson EL, Gold KN, Bloch DA, Hunder GG (1996) Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's granulomatosis classification criteria cohort. Am J Med 101:129–134CrossRefPubMed
4.
go back to reference Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH et al (2003) Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 41:776–784PubMedCrossRef Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH et al (2003) Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 41:776–784PubMedCrossRef
5.
go back to reference Nishino H, Rubino FA, DeRemee RA, Swanson JW, Parisi JE (1993) Neurological involvement in Wegener's granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol 33:4–9CrossRefPubMed Nishino H, Rubino FA, DeRemee RA, Swanson JW, Parisi JE (1993) Neurological involvement in Wegener's granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol 33:4–9CrossRefPubMed
6.
go back to reference Nishino H, Rubino FA, Parisi JE (1993) The spectrum of neurologic involvement in Wegener's granulomatosis. Neurology 43:1334–1337PubMed Nishino H, Rubino FA, Parisi JE (1993) The spectrum of neurologic involvement in Wegener's granulomatosis. Neurology 43:1334–1337PubMed
7.
go back to reference Murphy JM, Gomez-Anson B, Gillard JH, Antoun NM, Cross J, Elliott JD et al (1999) Wegener granulomatosis: MR imaging findings in brain and meninges. Radiology 213:794–799PubMed Murphy JM, Gomez-Anson B, Gillard JH, Antoun NM, Cross J, Elliott JD et al (1999) Wegener granulomatosis: MR imaging findings in brain and meninges. Radiology 213:794–799PubMed
8.
go back to reference Miller KS, Miller JM (1993) Wegener's granulomatosis presenting as a primary seizure disorder with brain lesions demonstrated by magnetic resonance imaging. Chest 103:316–318PubMedCrossRef Miller KS, Miller JM (1993) Wegener's granulomatosis presenting as a primary seizure disorder with brain lesions demonstrated by magnetic resonance imaging. Chest 103:316–318PubMedCrossRef
9.
go back to reference Oimomi M, Suehiro I, Mizuno N, Baba S, Okada S, Kanazawa Y (1980) Wegener's granulomatosis with intracerebral granuloma and mammary manifestation. Report of a case. Arch Intern Med 140:853–854CrossRefPubMed Oimomi M, Suehiro I, Mizuno N, Baba S, Okada S, Kanazawa Y (1980) Wegener's granulomatosis with intracerebral granuloma and mammary manifestation. Report of a case. Arch Intern Med 140:853–854CrossRefPubMed
10.
go back to reference Miesen WM, Janssens EN, van Bommel EF (1999) Diabetes insipidus as the presenting symptom of Wegener's granulomatosis. Nephrol Dial Transplant 14:426–429CrossRefPubMed Miesen WM, Janssens EN, van Bommel EF (1999) Diabetes insipidus as the presenting symptom of Wegener's granulomatosis. Nephrol Dial Transplant 14:426–429CrossRefPubMed
11.
go back to reference Katzman GL, Langford CA, Sneller MC, Koby M, Patronas NJ (1999) Pituitary involvement by Wegener's granulomatosis: a report of two cases. AJNR Am J Neuroradiol 20:519–523PubMed Katzman GL, Langford CA, Sneller MC, Koby M, Patronas NJ (1999) Pituitary involvement by Wegener's granulomatosis: a report of two cases. AJNR Am J Neuroradiol 20:519–523PubMed
12.
go back to reference Provenzale JM, Allen NB (1996) Wegener granulomatosis: CT and MR findings. AJNR Am J Neuroradiol 17:785–792PubMed Provenzale JM, Allen NB (1996) Wegener granulomatosis: CT and MR findings. AJNR Am J Neuroradiol 17:785–792PubMed
13.
go back to reference Haynes BF, Fauci AS (1978) Diabetes insipidus associated with Wegener's granulomatosis successfully treated with cyclophosphamide. N Engl J Med 299:764PubMedCrossRef Haynes BF, Fauci AS (1978) Diabetes insipidus associated with Wegener's granulomatosis successfully treated with cyclophosphamide. N Engl J Med 299:764PubMedCrossRef
14.
go back to reference Hurst NP, Dunn NA, Chalmers TM (1983) Wegener's granulomatosis complicated by diabetes insipidus. Ann Rheum Dis 42:600–601PubMedCrossRef Hurst NP, Dunn NA, Chalmers TM (1983) Wegener's granulomatosis complicated by diabetes insipidus. Ann Rheum Dis 42:600–601PubMedCrossRef
15.
go back to reference Garovic VD, Clarke BL, Chilson TS, Specks U (2001) Diabetes insipidus and anterior pituitary insufficiency as presenting features of Wegener's granulomatosis. Am J Kidney Dis 37:E5PubMedCrossRef Garovic VD, Clarke BL, Chilson TS, Specks U (2001) Diabetes insipidus and anterior pituitary insufficiency as presenting features of Wegener's granulomatosis. Am J Kidney Dis 37:E5PubMedCrossRef
Metadata
Title
Combined CNS and pituitary involvement as a primary manifestation of Wegener granulomatosis
Authors
Radek Špíšek
Elena Kolouchová
Jiří Jenšovský
Robert Rusina
Pavel Fendrych
Jaroslav Plas
Jiřina Bartůňková
Publication date
01-09-2006
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 5/2006
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-005-0065-5

Other articles of this Issue 5/2006

Clinical Rheumatology 5/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine